Valeo Health secures $12 million Series B for UAE diagnostic expansion

Valeo Health secured $12 million in Series B funding on March 26, 2025, bringing the company's total capital raised to $20 million. This investment supports the expansion of the firm's direct-to-consumer diagnostic platform across the UAE.

The company operates a mobile application where users book medical tests and review lab results. Valeo Health intends to use the capital to scale its laboratory partnerships and extend its network to additional clinical providers. For hospital operations heads, this growth signals higher patient demand for digital health portals that connect home-based testing with clinical record systems.

Expansion of diagnostic services in Dubai requires adherence to Dubai Health Authority licensing standards for mobile health and data management. As Valeo Health captures more of the diagnostics market, established healthcare groups face pressure to digitize patient intake and results delivery. Medical directors must monitor the integration of third-party health data into systems governed by the Dubai Health Authority to ensure compliance.

This funding round provides Valeo Health with the runway to scale while meeting data privacy requirements set by the Ministry of Health and Prevention. Startup founders in the region track these growth metrics as benchmarks for Series B valuations in the local health technology sector.